Technical Analysis for TARS - Tarsus Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Calm After Storm | Range Contraction | -0.88% | |
| Earnings Movers | Other | -0.88% | |
| Calm After Storm | Range Contraction | -0.68% | |
| NR7 | Range Contraction | -0.68% | |
| Earnings Movers | Other | -0.68% | |
| Gapped Up | Strength | -0.68% | |
| Calm After Storm | Range Contraction | 0.66% | |
| Upper Bollinger Band Touch | Strength | 0.66% | |
| Crossed Above 20 DMA | Bullish | 3.35% |
| Alert | Time |
|---|---|
| 10 DMA Support | 3 days ago |
| Down 3% | 3 days ago |
| Fell Below 10 DMA | 3 days ago |
| Fell Below Previous Day's Low | 3 days ago |
| Down 2 % | 3 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/15/2024
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Ophthalmic Malaria Rosacea Blepharitis Meibomian Gland
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Ophthalmic Malaria Rosacea Blepharitis Meibomian Gland
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.5 |
| 52 Week Low | 12.66 |
| Average Volume | 590,396 |
| 200-Day Moving Average | 23.83 |
| 50-Day Moving Average | 34.46 |
| 20-Day Moving Average | 35.28 |
| 10-Day Moving Average | 37.51 |
| Average True Range | 2.30 |
| RSI (14) | 59.51 |
| ADX | 34.81 |
| +DI | 28.97 |
| -DI | 11.25 |
| Chandelier Exit (Long, 3 ATRs) | 35.61 |
| Chandelier Exit (Short, 3 ATRs) | 37.11 |
| Upper Bollinger Bands | 40.56 |
| Lower Bollinger Band | 30.00 |
| Percent B (%b) | 0.78 |
| BandWidth | 29.94 |
| MACD Line | 1.20 |
| MACD Signal Line | 0.84 |
| MACD Histogram | 0.3588 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 41.05 | ||||
| Resistance 3 (R3) | 40.86 | 39.73 | 40.58 | ||
| Resistance 2 (R2) | 39.73 | 39.02 | 39.83 | 40.43 | |
| Resistance 1 (R1) | 38.99 | 38.57 | 38.42 | 39.18 | 40.27 |
| Pivot Point | 37.86 | 37.86 | 37.58 | 37.95 | 37.86 |
| Support 1 (S1) | 37.11 | 37.14 | 36.55 | 37.30 | 36.21 |
| Support 2 (S2) | 35.98 | 36.70 | 36.08 | 36.05 | |
| Support 3 (S3) | 35.24 | 35.98 | 35.90 | ||
| Support 4 (S4) | 35.43 |
